metformin has been researched along with pioglitazone in 491 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (1.22) | 18.2507 |
| 2000's | 177 (36.05) | 29.6817 |
| 2010's | 253 (51.53) | 24.3611 |
| 2020's | 55 (11.20) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kanojiya, S; Maurya, R; Mishra, A; Pandey, J; Patel, OP; Raju, KS; Saini, D; Shukla, SK; Srivastava, AK; Srivastava, MN; Tamrakar, AK; Taneja, I; Wahajuddin, M; Yadav, PP | 1 |
| Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
| Chen, R; Guo, B; Li, SM; Li, XS; Ma, X; Tang, L; Wu, HS; Zhang, JQ; Zhong, G; Zhou, B; Zhu, GF | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Kotchen, TA; Reddy, SR; Zhang, HY | 1 |
| Kawamori, R; Yoshii, H | 1 |
| Hodorek, MJ; Iannucci, AR; Peuler, JD; Phare, SM | 1 |
| Cwik, C; Mishra, SK; Postlethwaite, AE; Rajanna, B; Solomon, SS | 1 |
| Bourghli, M; Miller, JA; Peuler, JD; Soltis, EE; Sowers, JR; Zammam, HY | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Gonzales, N; Nadler, JL; Natarajan, R; Rahbar, S; Scott, S; Yerneni, K | 1 |
| Egan, JW; Einhorn, D; Mathisen, AL; Rendell, M; Rosenzweig, J; Schneider, RL | 1 |
| Arlt, W; Auchus, RJ; Miller, WL | 1 |
| Baba, T; Hashimoto, S; Neugebauer, S; Shimada, K; Watanabe, T; Yamada, D | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Ikeda, H; Odaka, H; Sugiyama, Y; Suzuki, M; Suzuki, N | 1 |
| Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L | 1 |
| Gao, X; Gao, Y; Jia, P; Li, G; Lin, H; Luo, B; Pan, C; Shi, H; Tian, H; Xing, X; Zhao, Y; Zhou, L | 1 |
| Braddon, J; Phillips, P | 1 |
| Iida, KT; Iwama, Y; Kamata, K; Kawakami, Y; Mokuno, H; Shimada, K; Shimano, H; Sone, H; Suzuki, M; Toyoshima, H; Watanabe, Y; Yamada, N | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Bruun, JM; He, G; Lihn, AS; Pedersen, SB; Richelsen, B | 1 |
| Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT | 1 |
| Moses, R | 1 |
| Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Henry, RR | 1 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Brunetti, P; Charbonnel, BH; Hanefeld, M; Matthews, DR; Schernthaner, GH | 1 |
| Diedrich, K; Ortmann, O; Schröder, AK; Tauchert, S; Weiss, JM | 1 |
| Bagool, MA; Deo, AA; Kolte, BL; Raut, BB; Shinde, DB | 1 |
| Aljabri, K; Kozak, SE; Thompson, DM | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Aiso, Y; Ishibashi, S; Nagasaka, S; Yoshizawa, K | 1 |
| Boyle, PJ; Buse, JB; Kendall, DM; Lau, H; Marchetti, A; Peters Harmel, AL | 1 |
| Khan, M; Murray, FT; Perez, A; Rajagopalan, R; Ye, Z | 1 |
| Althaym, A; Brunmair, B; Clara, R; Fürnsinn, C; Gnaiger, E; Gras, F; Nohl, H; Roden, M; Scharf, N; Staniek, K; Waldhäusl, W | 1 |
| Campbell, IW | 1 |
| Gilmore, KJ; Glazer, NB; Johns, D; Tan, MH; Widel, M | 1 |
| Dazzi, D; Hassan, H; Negro, R; Pezzarossa, A | 1 |
| Chandalia, HB; Fafadia, A; Joshi, SR; Panikar, V; Santvana, C | 1 |
| Croom, DK; Lenhard, JM; Minnick, DT | 1 |
| Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M | 1 |
| Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G | 1 |
| Edwards, G; Khan, M; Mariz, S; Urquhart, R; Xu, Y | 1 |
| Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A | 1 |
| Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U | 1 |
| Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A | 1 |
| Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V | 1 |
| Richards, RJ | 1 |
| Ceriello, A; Eckland, DJ; Gilmore, KJ; Johns, D; Tan, MH; Widel, M | 1 |
| Iyer, S; Perez, A; Rajagopalan, R | 1 |
| Fugate, SE; Stout, DL | 1 |
| Fernandes, AW; Lester, JW | 1 |
| McIntyre, HD; Morton, AP | 1 |
| Iyer, S; Khan, M; Rajagopalan, R | 1 |
| Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G; Tan, MH; Urquhart, R | 1 |
| Schumm-Draeger, PM | 1 |
| Belcher, G; Edwards, G; Lambert, C; Matthews, DR; Urquhart, R | 1 |
| Belcher, G; Schernthaner, G | 1 |
| Ichiyanagi, K; Igarashi, K; Kawasaki, T; Sakai, T; Watanabe, H; Yamanouchi, T | 1 |
| Johns, D; Laakso, M; Mariz, S; Richardson, C; Roden, M; Tan, MH; Urquhart, R; Widel, M | 1 |
| Hirosumi, J; Ita, M; Kawamura, I; Mabuchi, M; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S; Yamamoto, T | 1 |
| Di Gregorio, GB; Kern, PA; Lu, T; McGehee, RE; Miles, LM; Peterson, CA; Ranganathan, G; Rasouli, N; Varma, V; Yao-Borengasser, A | 1 |
| Elbein, SC; Kern, PA; Miles, LM; Rasouli, N; Yao-Borengasser, A | 1 |
| Goto, T; Igaki, N; Tanaka, M | 1 |
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Betteridge, DJ; Vergès, B | 1 |
| Johnson, T; Karunaratne, M; Khan, M; Perez, A | 1 |
| Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
| Chopra, D; Kinagi, SB; Langade, DG; Meshram, DM; Morye, V; Naikwadi, AA | 1 |
| Ahn, CW; Cha, BS; Kim, HJ; Kim, SK; Lee, HC; Lee, YJ; Park, CW; Shim, WS; Zhao, ZS | 1 |
| El Beltagy, K; Honda, K; Ishiko, O; Misugi, T; Ozaki, K; Tokuyama, O | 1 |
| Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R | 1 |
| Galle, PR; Siebler, J | 1 |
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Issa, M; Umpierrez, G; Vlajnic, A | 1 |
| Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K | 1 |
| Smits, P; Tack, CJ | 1 |
| Dorkhan, M; Frid, A; Groop, L; Hallengren, B; Lantz, M | 1 |
| Araki, T; Emoto, M; Hatsuda, S; Inaba, M; Koyama, H; Maeno, T; Mori, K; Nishizawa, Y; Shinohara, K; Shoji, T; Teramura, M; Yokoyama, H | 1 |
| Forst, T; Hanefeld, M; Lübben, G; Pfützner, A | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 2 |
| Dorkhan, M; Frid, A; Groop, L; Grubb, A; Jovinge, S; Magnusson, M | 1 |
| Staels, B | 1 |
| Seufert, J | 1 |
| Forst, T; Pfützner, A; Schneider, CA | 1 |
| Elbein, SC; Kern, PA; Rasouli, N; Reece, EA | 1 |
| Deeks, ED; Scott, LJ | 1 |
| Daita, H; Mokuno, H; Tamura, H | 1 |
| Bouma, M; Rutten, GE; Wiersma, T | 1 |
| Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A | 1 |
| Bhansali, A; Malhotra, S; Pandhi, P; Sharma, PK; Sialy, R | 1 |
| Kanazawa, Y; Oikawa, Y; Okubo, Y; Shigihara, T; Shimada, A | 1 |
| Bottomley, J; Diamantopoulos, A; Mariz, S; O'Bryan-Tear, G; Tilden, DP | 1 |
| Bradford, D; Cao, C; Karim, A; Laurent, A; Schwartz, L; Slater, M; Zhao, Z | 1 |
| Bradford, D; Karim, A; Laurent, A; Schwartz, L; Slater, M | 1 |
| Allemann, S; Braun, M; Chappuis, B; Christ, ER; Diem, P; James, R; Lumb, PJ; Stettler, C; Wierzbicki, AS | 1 |
| de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C | 1 |
| Adams-Huet, B; Jacob, AN; Raskin, P; Salinas, K | 1 |
| Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H | 1 |
| Hitch, WJ; Jackson, VL; Scott, MA | 1 |
| Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS | 1 |
| Willeke, A | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Salvadeo, SA | 1 |
| Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rashidi, AA; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A | 1 |
| Bussel, II; Felgner, J; Jafari, M; Khodayari, B; Mueller, LD; Rose, MR | 1 |
| Bellatreccia, A; Comaschi, M; Demicheli, A; Di Pietro, C; Mariz, S | 1 |
| Baird, J; Campbell, IW; Chalmers, J; Franks, CI; Hunter, JE; Mariz, S; Martin, M; Robertson, SJ; Whately-Smith, CR | 1 |
| Hill, NR; Matthews, DR | 1 |
| Balaska, A; Kakavas, N; Karagiannis, A; Koulas, G; Kountana, E; Sambanis, C; Tziomalos, K; Zamboulis, C; Zografou, I | 1 |
| Bukkawar, A; Joshi, SR; Nasikkar, N; Panikar, V; Santwana, C | 1 |
| Fujii, M; Hirota, Y; Kasuga, M; Kawamitsu, H; Kouyama, K; Maeda, K; Ohara, T; Sugimura, K; Teranishi, T; Zenibayashi, M | 1 |
| Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P | 2 |
| Bellatreccia, A; Comaschi, M; Corsi, A; Di Pietro, C; Mariz, S | 1 |
| Braceras, R; Chaykin, L; Chu, PL; Matfin, G; Raskin, P; Schwartz, SL; Wynne, A | 1 |
| Chalasani, N; Khashab, M | 1 |
| de Zegher, F; Díaz, M; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C | 1 |
| Bolli, G; Cohen, SE; Dotta, F; Rochotte, E | 1 |
| Ahrén, B | 2 |
| Atkin, SL; Cho, LW | 1 |
| Seufert, J; Urquhart, R | 1 |
| Wild, RA | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y | 1 |
| Drucker, DJ; Goldberg, RB; Holman, R | 1 |
| Halperin, F; Ingelfinger, JR; McMahon, GT | 1 |
| Glueck, C; Goldenberg, N | 1 |
| Horie, H; Ishibashi, S; Kusaka, I; Nagasaka, S | 1 |
| Koro, CE; Landon, J; Walker, AM | 1 |
| Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES | 1 |
| Atsumi, Y; Funae, O; Hirata, T; Itoh, H; Kawai, T; Shimada, A; Tabata, M | 1 |
| Amin, M; Jain, D; Jain, S | 1 |
| Aoki, TJ; White, RD | 1 |
| Bodles, AM; Kern, PA; McGehee, RE; Phanavanh, B; Ranganathan, G; Rasouli, N; Rassouli, N; Unal, R; Varma, V; Yao-Borengasser, A | 1 |
| Araki, T; Emoto, M; Inaba, M; Koyama, H; Lee, E; Mori, K; Nishizawa, Y; Shoji, T; Teramura, M; Yokoyama, H | 1 |
| Bozoglu, E; Dogru, T; Ercin, CN; Erdem, G; Muhsiroglu, O; Sonmez, A; Tapan, S; Tasci, I | 1 |
| Dieterich, HA; Dole, WP; Howard, D; Maboudian, M; Vaidyanathan, S; Warren, V; Yeh, CM | 1 |
| Biasucci, LM; Buffon, A; Crea, F; Di Stasio, E; Ghirlanda, G; Giubilato, S; Liuzzo, G; Pitocco, D; Zaccardi, F | 1 |
| Dorkhan, M; Frid, A; Groop, L | 1 |
| Sano, H; Tajima, N | 1 |
| de Zegher, F; del Río, L; Díaz, M; Enríquez, G; Ibáñez, L; López-Bermejo, A | 2 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Mesa, J; Polavieja, P; Reviriego, J; Rodríguez, A | 1 |
| Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A | 1 |
| Amoli, MM; Bandarian, F; Tehrani, MR; Valizadeh, N | 1 |
| Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA | 1 |
| Bray, GA; Greenway, FL; Gupta, AK; Smith, SR | 1 |
| Brazzale, AR; Mariz, S; Pacini, G; Roden, M | 1 |
| Kaku, K | 2 |
| Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW | 1 |
| Gropler, RJ | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Joly, E; Lamontagne, J; Madiraju, SR; Nolan, CJ; Pepin, E; Peyot, ML; Poitout, V; Prentki, M; Ruderman, NB | 1 |
| Dhawan, A; Dziechciarz, P; Horvath, A; Socha, P; Szajewska, H; Vajro, P | 1 |
| Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL | 1 |
| Forst, T; Karagiannis, E; Pfützner, A; Posseldt, RE; Schöndorf, T | 1 |
| Retnakaran, R; Zinman, B | 1 |
| Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B | 1 |
| Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW | 1 |
| Adams-Huet, B; Kaloyanova, PF; Legendre, JL; Lingvay, I; Raskin, P; Zhang, S | 1 |
| Charpentier, G; Halimi, S | 1 |
| Demirci, M; Ersoy, C; Erturk, E; Imamoglu, S; Kiyici, S; Oz Gul, O; Sarandol, E; Sigirli, D; Tuncel, E | 1 |
| Kern, PA; McGehee, RE; Mehta, JL; Peterson, CA; Rasouli, N; Spencer, HJ; Varma, V; Yao-Borengasser, A | 1 |
| Derosa, G; Maffioli, P; Tinelli, C | 1 |
| Jacks, R; Perez, A; Spanheimer, R; Zhao, Z | 1 |
| Betteridge, DJ; Birkeland, K; Charbonnel, B; Scheen, AJ; Schmitz, O; Tan, MH | 2 |
| Bax, JJ; de Roos, A; Diamant, M; Jonker, JT; Lamb, HJ; Menting, LJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW | 1 |
| Hayakawa, N; Itoh, M; Kanayama, H; Katada, N; Kato, T; Oda, N; Sawai, Y; Suzuki, A; Taguchi, H; Taki, F; Terabayashi, T; Yamada, K; Yamazaki, Y | 1 |
| Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kim, HJ; Kim, SK; Lee, BW; Lee, HC; Moon, JH | 1 |
| Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S | 1 |
| Dikta, G; Forst, T; Fuchs, W; Hehenwarter, S; Hohberg, C; Kerschgens, B; Kleine, I; Musholt, PB; Pfützner, A; Schöndorf, T | 1 |
| de Haan, W; de Roos, A; Diamant, M; Jonker, JT; Lamb, HJ; Rensen, PC; Rijzewijk, LJ; Romijn, JA; Smit, JW; Tamsma, JT; van der Meer, RW; Wang, Y | 1 |
| Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Ishihara, K; Kitagawa, Y; Nakamura, N; Nakano, K; Obayashi, H; Ogata, M; Ohta, M; Takashima, T; Yamasaki, M | 1 |
| Ciprés, L; Polavieja, P; Reviriego, J; Rodríguez, A; Tofé, S | 1 |
| El-Ghobashy, MR; Hegazy, MA; Mostafa, AA; Yehia, AM | 1 |
| Burnier, M; Deleaval, P; Jornayvaz, FR; Maillard, M; Nussberger, J; Pechere-Bertschi, A; Vinciguerra, M; Zanchi, A | 1 |
| Forst, T; Friedrich, C; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Pfützner, A; Weber, MM | 1 |
| Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T | 1 |
| Ehssan, NA; Gad, MZ; Ghiet, MH; Wahman, LF | 1 |
| Larson, RJ; Sheth, SH | 1 |
| Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
| Meier, JJ; Nauck, MA | 2 |
| Brady, JD; Crowther, D; Feuerstein, GZ; Grierson, CE; Hansen, MK; Hundal, HS; Logie, L; Morris, AD; Pearson, E; Ruiz-Alcaraz, AJ; Schofield, CJ; Shepherd, B; Sutherland, C; Tommasi, AM | 1 |
| Droege, M; Farley, JF; Hansen, RA; Maciejewski, ML | 1 |
| Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A | 1 |
| Hatzitolios, AI; Katsiki, N | 1 |
| Brouwers, MC; de Graaf, J; Schaper, N; Stalenhoef, AF; Stehouwer, CD; van Greevenbroek, MM | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA | 1 |
| Ahn, CW; Cha, BS; Cho, MH; Kim, KR; Lee, HC; Nam, JS; Park, JS; Yoo, JS | 1 |
| Li, XJ; Liu, CQ; Wang, LY; Yan, B; Yang, SY; Yu, YX; Zhang, HJ; Zhang, SH; Zhang, W | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Arora, V; Jacks, R; Perez, A; Spanheimer, R | 1 |
| Coker, RH; Kern, PA; Phanavanh, B; Ranganathan, G; Rasouli, N; Varma, V; Yao-Borengasser, A | 1 |
| Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J | 1 |
| Bron, M; Chen, KS; Mattson, ME; McCall, T; Pandya, BJ; Wu, EQ; Yu, AP | 1 |
| Archimandritis, A; Charalampidou, E; Drossinos, V; Karamanos, B; Sourmeli, S; Thanopoulou, A | 1 |
| Bellastella, G; Di Palo, C; Esposito, K; Gicchino, M; Giugliano, D; Maiorino, MI; Petrizzo, M; Saccomanno, F | 1 |
| Benjasuratwong, Y; Patarakitvanit, S; Satyapan, N; Temboonkiat, S; Vudhironarit, T | 1 |
| Cersosimo, E; Cervera, A; DeFronzo, RA; Fernandez, M; Ghosh, S; Joya-Galeana, J; Musi, N; Reyna, S; Triplitt, C | 1 |
| del Cañizo, FJ; Drossinos, V; Karamanos, V; Reviriego, J; Rodríguez, A; Vlachogiannis, N | 1 |
| Boulton, DW; Brenner, E; Handschuh del Corral, M; Komoroski, B; Kornhauser, D; Li, L; Patel, CG; Vachharajani, N | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D | 1 |
| Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamamoto, M | 1 |
| Bell, DS; Dharmalingam, M; Kumar, S; Sawakhande, RB | 1 |
| Asai, Y; Atsumi, Y; Kabeya, Y; Katsuki, T; Meguro, S; Oikawa, Y; Shimada, A; Tomita, M | 1 |
| Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Bajaj, M; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P | 1 |
| Bosi, E; Ellis, GC; Fleck, PR; Wilson, CA | 1 |
| Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Pfützner, A | 1 |
| Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H | 1 |
| Barner, JC | 1 |
| Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L | 1 |
| de Zegher, F; Diaz, M; Ibáñez, L; Lopez-Bermejo, A; Salvador, C; Sánchez-Infantes, D; Sebastiani, G | 1 |
| Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P | 1 |
| Al-Azzam, SI; Almahasneh, FA; Alomari, M; Altawalbeh, S; Khader, YS; Muflih, SM | 1 |
| Scheen, AJ | 1 |
| Bechlioulis, A; Kanioglou, C; Kazakos, N; Kostoula, A; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A; Vezyraki, P | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L | 1 |
| Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N | 1 |
| Baraka, AM; Deif, MM | 1 |
| Katsuki, T; Oikawa, Y; Okubo, Y; Shigihara, T; Shimada, A; Yamada, Y | 1 |
| Jermendy, G | 1 |
| Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J | 1 |
| Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP | 1 |
| Dong, JJ; Liao, L; Mou, YR; Qiu, LL; Yang, M; Zhao, JJ | 1 |
| Beltran, A; Bladé, C; Correig, X; Díaz, M; Ibañez, L; Mallol, R; Rodriguez, MA; Samino, S; Vinaixa, M; Yanes, O | 1 |
| Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
| Diamant, M; Hamdy, NA; Jonker, JT; Lamb, HJ; Papapoulos, SE; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW; van Lierop, AH | 1 |
| Elrod, S; Harrington, C; McLaughlin-Middlekauff, J; Singh-Franco, D | 1 |
| Burant, CF; DeFronzo, RA; Fleck, P; Mekki, Q; Pratley, RE; Wilson, C | 1 |
| Erdogdu, O; Eriksson, L; Nyström, T; Sjöholm, Å; Zhang, Q | 1 |
| Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A | 1 |
| Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
| Alonso, E; Aparicio, I; Buchberger, W; Martín, J; Santos, JL | 1 |
| Janczyk, W; Socha, P | 1 |
| Balena, R; Henry, RR; Kanitra, L; Mudaliar, S; Woloschak, M | 1 |
| Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y | 1 |
| Carter, RE; Chow, L; Irving, BA; McCoy, RG; Nair, KS; Soop, M; Srinivasan, M; Tatpati, L; Weymiller, AJ | 1 |
| Frier, BM; Inkster, B; Zammitt, NN | 1 |
| Adams-Huet, B; Harrison, LB; Lingvay, I; Raskin, P | 1 |
| Maegawa, H; Ugi, S | 1 |
| Chacón, MR; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Maymó-Masip, E; Salvador, C; Vendrell, J | 1 |
| Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS | 1 |
| Bhansali, A; Sachdeva, N; Sridhar, S; Walia, R | 1 |
| Chen, SG; Cheng, XY; He, JW; Li, H; Lu, ML; Qu, S; Sheng, CJ; Wang, C; Wang, KS; Yu, YC | 1 |
| Balena, R; Boldrin, M; Pratley, RE; Urosevic, D | 1 |
| Choi, MG; Jung, JS; Kang, YJ; Kim, CH; Kim, SJ; Kim, SS; Park, SH; Ryu, OH; Sim, YB; Suh, HW | 1 |
| Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES | 1 |
| Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME | 1 |
| Hou, WK; Huang, QX; Li, MZ; Lin, P; Liu, Q; Song, J; Wang, K; Wang, Q; Xu, H; Yu, S; Zhang, L; Zhang, Y | 1 |
| Bonora, E; Del Prato, S; Giorda, CB; Maggioni, AP; Masulli, M; Mocarelli, P; Nicolucci, A; Riccardi, G; Rivellese, AA; Squatrito, S; Vaccaro, O | 1 |
| Ahmet, D; Cigdem, E; Ece, H; Hakan, E; Oktay, TM; Yuksel, K | 1 |
| Esteghamati, A; Kebriaee-Zadeh, A; Nakhjavani, M; Rashidi, A; Taslimi, S; Tavakkoli, HM | 1 |
| Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S | 1 |
| Peng, Y; Sun, J; Wan, P; Wang, G; Yin, L; Zhang, X | 1 |
| Beydoun, H; Beydoun, M; Kancherla, V; Stadtmauer, L | 1 |
| Esteghamati, A; Ghavami, M; Nakhjavani, M; Noshad, S; Rabizadeh, S; Zandieh, A | 1 |
| Ceriello, A; De Berardis, G; Evangelista, V; Genovese, S; Mannucci, E; Nicolucci, A; Pellegrini, F; Totani, L | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
| Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A | 1 |
| D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T | 1 |
| Aronson, R; Goldenberg, R; Guo, H; Muehlen-Bartmer, I; Niemoeller, E; Pinget, M | 1 |
| Bharathi, DV; Jagadeesh, B; Narayana, VS; Pankaj, C; Venkateswarulu, V | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ | 1 |
| Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR | 1 |
| Marangoni, A; Zenari, L | 1 |
| Bhattacharya, S; Durán-Garcia, S; Patel, S; Pinnetti, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H | 1 |
| Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL | 1 |
| Chen, WJ; de Roos, A; Diamant, M; Greulich, S; Lamb, HJ; Lammertsma, AA; Lubberink, M; Ouwens, DM; Rijzewijk, LJ; Romijn, JA; Ruige, JB; Smit, JW; van der Meer, RW | 1 |
| Li, H; Lu, J; Zang, J | 1 |
| Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Cui, T; Mao, Y; Tang, D; Wang, XL; Wang, Z | 1 |
| Erowele, G; Ndefo, UA; Okoli, O | 1 |
| de Pablos-Velasco, PL; Valerón, PF | 1 |
| Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Bernlohr, DA; Hahn, WS; Xu, Q | 1 |
| Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A | 1 |
| Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM | 1 |
| Agrawal, N; Bhandari, S; Chandurkar, N; Deshpande, A; Devaramani, S; Gupta, OP; Kakrani, A; Kothari, K; Mahesh, M; Pareek, A; Saboo, B; Shah, A; Sharma, S; Thomas, N; Thulasidharan, NK; Vijaykumar, NB; Viswanathan, V | 1 |
| Ceriello, A; Gourdy, P; Raccah, D; Sagnard, L | 1 |
| Civan, N; Deger, O; Erem, C; Ersoz, HO; Nuhoglu, I; Ozbas, HM | 1 |
| DePaoli, AM; Dunn, FL; Henry, RR; Higgins, LS; Mantzoros, C | 1 |
| Cleall, S; Gross, JL; Onaca, A; Rodríguez, A; Tinahones, FJ | 1 |
| Kabiri, N; Tabandeh, MR; Tabatabaie, SR | 1 |
| de Zegher, F; Dunger, DB; Ibáñez, L; López-Bermejo, A; Ong, KK | 1 |
| Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ | 1 |
| Arakaki, R; Atisso, C; Blevins, T; Colon, G; Garcia, P; Kuhstoss, D; Lakshmanan, M; Wysham, C | 1 |
| Ahrén, B; Chow, FC; Fonseca, VA; Gross, JL; Johnson, SL; Leiter, LA; Miller, D; Ratner, RE; Rosenstock, J; Stewart, MW; Yang, F | 1 |
| Agarwal, SK; Singh, BK; Wadhwa, R | 1 |
| Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC | 1 |
| Bron, M; Joseph, G; Liang, H; Perez, A; Vallarino, C; Yang, J; Yu, S | 1 |
| Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF | 1 |
| Shou, L; Song, MQ; Yang, L; Yang, YL; Zang, SF; Zhang, QL | 1 |
| Ebadi, M; Esteghamati, A; Khajeh, E; Nakhjavani, M; Noshad, S; Rezvani, S | 1 |
| Bode, BW; Cirkel, DT; Perkins, CM; Perry, CR; Reinhardt, RR; Reusch, J; Stewart, MW; Ye, J | 1 |
| Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S | 1 |
| Khatu, S; Poojary, S | 1 |
| Curtin, CR; Ford, L; Heald, D; Manitpisitkul, P; Shalayda, K; Wang, SS | 1 |
| He, W; Li, Y; Wu, Z; Yin, L; Zhang, R | 1 |
| DeGeeter, M; Williamson, B | 1 |
| Ampudia-Blasco, FJ; Benhamou, PY; Charpentier, G; Consoli, A; Diamant, M; Gallwitz, B; Khunti, K; Mathieu, C; Phan, TM; Ridderstråle, M; Seufert, J; Stoevelaar, H; Tack, C; Vilsbøll, T | 1 |
| Carr, MC; Home, PD; Miller, M; Perry, C; Shamanna, P; Stewart, M; Yang, F | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Herrigel, DJ; Moss, RA | 1 |
| Abdul-Ghani, MA; Adams, J; Cersosimo, E; DeFronzo, RA; Maggs, D; Puckett, C; Triplitt, C | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Ahn, CW; Baik, SH; Cha, BS; Cho, YM; Jin, SM; Ku, BJ; Lee, KW; Lee, MK; Min, KW; Park, CY; Park, SW; Sung, YA; Yoon, KH | 1 |
| Afarideh, M; Azizi, R; Ebadi, M; Esteghamati, A; Mousavizadeh, M; Nakhjavani, M; Noshad, S | 1 |
| Baig, SG; Khan, RA; Siddiq, A | 1 |
| Barazzoni, R; Bhagra, S; Carter, RE; Irving, BA; Karakelides, H; Nair, KS; Short, KR; Soop, M; Syed, H; Tatpati, L; Weymiller, A | 1 |
| Douglas, MW; George, J; McLauchlan, J; Read, SA; Shahidi, M; Tay, ES | 1 |
| Byrne, FM; Chapman, V; Cheetham, S; Vickers, S | 1 |
| Nagai, Y | 1 |
| Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H | 1 |
| Doblhammer, G; Fink, A; Heneka, MT | 1 |
| Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
| Bode, BW; Buse, JB; Gough, SC; Linjawi, S; Reiter, PD; Rodbard, HW; Woo, VC; Zacho, M | 1 |
| Chang, Y; Choi, NK; Kim, JY; Kim, YJ; Lee, J; Park, BJ; Seong, JM; Shin, JY | 1 |
| George, TM; Jennings, AS; Jennings, JS; Lovett, AJ | 1 |
| Peuler, JD; Phelps, LE | 1 |
| Hayashi, Y; Ishii, M; Matsumoto, Y; Miyazaki, S; Sekimizu, K; Sugita, T; Sumiya, E | 1 |
| Gupta, Y; Kalra, S | 1 |
| Ahmed, S; Mohamed, AM; Mohamed, FA; Mohamed, YA | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Kovacs, CS; Merker, L; Roux, F; Salsali, A; Seshiah, V; Stella, P; Woerle, HJ | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| D'Angelo, A; Derosa, G; Maffioli, P | 1 |
| Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L | 1 |
| de Zegher, F; Díaz, M; Gallego-Escuredo, JM; Ibáñez, L; Villarroya, F | 1 |
| Ayuob, N; Murad, H | 1 |
| Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D | 1 |
| Zhang, X; Zhao, Q | 1 |
| Bu, R; Gu, W; Han, P; Ji, Q; Jiang, Z; Lei, M; Li, C; Li, L; Li, W; Li, X; Li, Z; Liu, J; Liu, X; Liu, Y; Liu, Z; Lu, J; Lyu, X; Pan, C; Peng, Y; Qu, S; Shi, B; Song, Q; Xu, X; Xue, Y; Yan, L; Yang, J; Zeng, J; Zheng, B | 1 |
| Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C | 1 |
| Lee, DK; Szabo, E | 1 |
| Correale, J; Farez, MF; Negrotto, L | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Indran, IR; Lee, BH; Yong, EL | 1 |
| Chan, J; Han, P; Hsieh, AT; Ji, Q; Li, C; Li, W; Lu, J; Pan, C; Yang, J; Zeng, J | 1 |
| Chung, CH; Duan, R; Edralin, DM; Han, JH; Jeong, IK; Rodriguez, A; Zhou, Z | 1 |
| Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
| Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S | 1 |
| Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MA | 1 |
| Crowe, S; Hach, T; Lee, J; Nishimura, R; Salsali, A; Woerle, HJ; Yoon, KH | 1 |
| Chen, YT; Liu, YM; Ou, HT; Wu, JS | 1 |
| Altinoz, MA; Elmaci, İ | 1 |
| Bhansali, A; Singh, S | 1 |
| Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I | 1 |
| Bastyr, EJ; Bue-Valleskey, JM; Chang, AM; Cusi, K; Hartman, ML; Haupt, A; Higdon, AN; Hoogwerf, BJ; Jacober, SJ; Sanyal, AJ; Zhang, S | 1 |
| Broglio, F; Mannucci, E; Napoli, R; Nicolucci, A; Nikonova, E; Purrello, F; Stager, W; Trevisan, R | 1 |
| Chen, HS; Chen, YH; Tarng, DC | 1 |
| Ahmed, AS; Al-Najjar, AH; El-Gharabawy, RM | 1 |
| Antonides, JD; Clapper, ML; Galbraith, AR; Haynes, AM; Miller, KA; Miller, MS; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Wuertz, BR | 1 |
| Caletti, MT; Forlani, G; Marchesini, G; Marchignoli, F; Mazzotti, A | 1 |
| Miyagi, K; Mutoh, A; Takasu, N; Yabiku, K | 1 |
| Goricar, K; Janez, A; Jensterle, M | 1 |
| Kshirsagar, NA; Pai, SA | 1 |
| Anabtawi, A; Miles, JM; Moriarty, PM | 1 |
| Chen, W; Liu, X; Mei, T; Ye, S | 1 |
| Grajower, MM; Kasher-Meron, M | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Barger, JL; Cray, NL; Hester, SN; Mastaloudis, A; Newton, MA; Prolla, TA; Pugh, TD; Vann, JM; Weindruch, R; Wood, SM | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T | 1 |
| de Zegher, F; Del Río, L; Díaz, M; Ibáñez, L; López-Bermejo, A; Pozo, ÓJ; Sebastiani, G | 1 |
| Elisaf, M; Filippatos, T; Liamis, G; Rizos, C; Tzavella, E | 1 |
| Huang, Q; Wu, Y; Xu, Y | 1 |
| Kang, DR; Kim, DJ; Lee, KJ; Lee, S; Noh, Y; Shin, S | 1 |
| Anichini, R; Antenucci, D; Babini, AC; Boemi, M; Bonora, E; Bossi, AC; Buzzetti, R; Calabrese, M; Cannarsa, E; Cappellini, F; Citro, G; Clemente, G; Consoli, A; Cordera, R; Corsi, L; Dall'Aglio, E; De Cosmo, S; Del Prato, S; di Bartolo, P; Di Benedetto, A; Di Cianni, G; Dotta, F; Fornengo, P; Giorda, CB; Giordano, C; Giorgino, F; Gnasso, A; Gregori, G; Iannarelli, R; Iovine, C; La Macchia, O; Lapolla, A; Lauro, D; Leotta, S; Lucisano, G; Maggioni, AP; Masulli, M; Mocarelli, P; Nicolucci, A; Perriello, G; Pugliese, G; Riccardi, G; Ricci, L; Rivellese, AA; Sacco, M; Santini, C; Scaranna, C; Sesti, G; Signorini, S; Squatrito, S; Tonutti, L; Vaccaro, O; Vedovato, M; Zamboni, C; Zavaroni, D | 1 |
| Carmona-Nimo, E; Castilla-Guerra, L; Fernandez-Moreno, MDC; Leon-Jimenez, D | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY | 1 |
| Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E | 1 |
| Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA | 1 |
| He, BC; Hu, XL; Hu, XN; Liao, YP; Liu, RX; Ma, Y; Sun, WJ | 1 |
| Anandan, V; Kartha, CC; Kutty, VR; Mullasari, A; Pillai, MR; Ramachandran, S | 1 |
| Abdel-Aziz, O; Ayoub, BM | 1 |
| Ishii, Y; Kume, S; Maekawa, T; Matsui, T; Miyajima, K; Ohta, T; Saito, T; Toriniwa, Y; Uno, K; Yamada, T | 1 |
| Al-Assi, O; Eid, AH; El-Yazbi, AF; Ghali, R; Kaplan, A; Mougharbil, N; Mroueh, A; Zouein, FA | 1 |
| Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D | 1 |
| Masulli, M; Riccardi, G; Vaccaro, O | 1 |
| Iogna Prat, L; Tsochatzis, EA | 1 |
| Anagnostis, P; Athyros, VG; Christou, K; Gkekas, NK; Karagiannis, A; Kosmidou, N; Siolos, P | 1 |
| Chang, CH; Chen, PC; Chuang, LM; Dong, YH; Ko, WC; Wang, JL; Wu, LC | 1 |
| Bhatia, A; Dayal, D; Kumar, R; Pilania, RK | 1 |
| Patel, R; Shah, G | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Abdul-Ghani, M; Armato, JP; DeFronzo, RA; Ruby, RJ | 1 |
| Damle, L; Gomez-Lobo, V; Sullivan, S; Uliassi, N | 1 |
| Afarideh, M; Alemi, H; Asadi Komeleh, S; Esteghamati, A; Esteghamati, S; Khaloo, P; Mansournia, MA; Mohammadi, A; Nakhjavani, M; Yadegar, A | 1 |
| de Zegher, F; Garcia-Beltran, C; Ibáñez, L; López-Bermejo, A; Malpique, R; Sánchez-Infantes, D; Taxerås, SD | 1 |
| Abdel Salam, RA; Abdelhady, KK; El-Wekil, MM; Hadad, GM | 1 |
| Ahn, BN; Hur, DY; Jang, JE; Kim, D; Kim, MK; Kim, TN; Kim, Y; Kwon, MJ; Lee, EJ; Lee, SH; Park, GB; Park, JH; Rhee, BD; Yang, JW | 1 |
| Anushiravani, A; Haddadi, N; Mohammadkarimi, V; Pourfarmanbar, M | 1 |
| Catena, G; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D; Tritto, I | 1 |
| Abdullah, AM; Fakhre, NA; M Amin, KF | 1 |
| Craig, A; Issberner, J; Parvez, F | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Abd-Elrahman, KS; Eid, AA; Eid, AH; El-Yazbi, AF; Elgaddar, O; Elkhatib, MAW; Fouad, H; Fouda, MA; Issa, K; Mroueh, A; Rafeh, RW; Saad, EI; Sleiman, F | 1 |
| Davidson, MB; Duran, P; Hsia, SH; Lee, ML | 1 |
| de Zegher, F; Ibáñez, L | 1 |
| Ali, A; Ali, DE; Badshah, H; Ehtesham, E; Malik, MO; Rehman, F; Shah, M; Vitale, SG | 1 |
| Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A | 1 |
| Liu, YT; Long, SL; Mo, ZC; Xie, YJ; Zeng, X | 1 |
| Blazina, I; Selph, S | 1 |
| Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA | 1 |
| Cereijo, R; de Zegher, F; García-Beltran, C; Ibáñez, L; López-Bermejo, A; Malpique, R; Quesada-López, T; Villarroya, F | 1 |
| Bombicz, M; Hegedűs, C; Juhász, B; Kiss, R; Kovács, D; Németh, J; Priksz, D; Szabó, AM; Szilvássy, Z; Varga, B; Wachal, Z | 1 |
| Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H | 1 |
| Biray Avci, C; Caliskan Kurt, C; Erdogan, M; Gunduz, C; Ozdemir Kutbay, N; Sarer Yurekli, B; Shademan, B | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Brandon, R; Doherty, G; Griffiths, D; Harré Hindmarsh, J; Jiang, Y; Macaskill-Smith, K; Merriman, TR; Moffitt, A; Murphy, R; Orr-Walker, B; Paul, R; Smallman, K; Yeu, RQ | 1 |
| Ferrannini, E; Katsiki, N | 1 |
| Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH | 1 |
| Berk, M; Ekstrøm, CT; Gerds, TA; Kessing, LV; Knop, FK; Rytgaard, HC | 1 |
| Brotons, P; Carbonetto, B; de Zegher, F; Garcia-Beltran, C; González-Torres, P; Henares, D; Ibáñez, L; López-Bermejo, A; Malpique, R; Muñoz-Almagro, C | 1 |
| Chi, Y; Hemmingsen, B; Ipsen, EØ; Madsen, KS; Metzendorf, MI; Pedersen-Bjergaard, U; Richter, B | 1 |
| Cairó, M; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J | 1 |
| Fu, J; Lian, J | 1 |
| Fu, BY; Wang, XJ | 1 |
| Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H | 1 |
| Ackermans, MT; Benthem, L; Binnendijk, G; Hulst, M; Koopmans, SJ; Mroz, Z; van Beusekom, HMM; van der Staay, FJ | 1 |
| Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N | 2 |
| Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S | 1 |
| Aggarwal, H; Dikshit, M; Jagavelu, K; Kumar, Y; Pathak, P | 1 |
| Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA | 1 |
| Akarsu, E; Balci, SO; Bozdag, Z; Demirel, C; Korkmaz, M; Lule, KO; Lule, NO; Sayiner, ZA; Yilmaz, I | 1 |
| Mistry, KY; Prajapati, PB; Shah, SA | 1 |
| Choi, SH; Chun, SW; Hur, KY; Jeong, IK; Kang, ES; Kim, HJ; Kim, SK; Noh, JH; Rhee, EJ | 1 |
| Burnet, P; Lennox, B; Minichino, A; Nibber, A; Singh, H | 1 |
| Eleftheriadou, I; Gavriatopoulou, M; Malandrakis, P; Ntanasis-Stathopoulos, I; Tentolouris, A; Tzeravini, E | 1 |
| Tseng, CH | 1 |
| Abdul-Ghani, MA; Adams, AC; Adams, J; Cersosimo, E; Cheng, CC; DeFronzo, RA; Fourcaudot, M; Heikkinen, S; Khattab, A; Norton, L; Puckett, C; Samms, RJ; Triplitt, C; Tsintzas, K | 1 |
| Vergès, B | 1 |
| Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS | 1 |
| Cheng, MZ; Gao, Y; Liu, L; Zhan, ZT; Zhou, WJ | 1 |
| Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A | 1 |
| Ehtesham, E; Habib, SH; Hassan, S; Malik, MO; Rauf, B; Shah, M | 1 |
| Candido, R; Gallo, M; Giaccari, A; Mannucci, E; Monami, M; Pintaudi, B; Targher, G | 1 |
| Katsiki, N; Kazakos, K; Triposkiadis, F | 1 |
| Hajek, T; Toba-Oluboka, T; Vochosková, K | 1 |
| Angwin, CD; Britten, N; Hattersley, AT; Holman, R; Jones, AG; Pearson, ER; Sattar, N; Shepherd, MH; Shields, BM | 1 |
| Onal, T; Tulay, P; Vatansever, HS | 1 |
| Bassols, J; Carreras-Badosa, G; de Zegher, F; Garcia-Beltran, C; Ibáñez, L; López Bermejo, A | 1 |
| He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H | 1 |
| Alnajjar, AO; AlThikrallah, MKI; Buzid, A; Elbashir, AA; Elgorashe, REE; Idris, AM | 1 |
| Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S | 1 |
| de Zegher, F; Díaz, M; Ibáñez, L | 1 |
| Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z | 1 |
| Elkhodary, MM; Hammad, SF; Kamal, AH; Marie, AA; Salim, MM | 1 |
| Chen, CC; Chen, LC; Chien, WC; Chung, CH; Huang, KY; Lin, HA; Lin, HC; Tsai, MH; Wang, JY | 1 |
| Chen, Z; Huang, Q; Huang, Y; Lai, X; Liu, D; Liu, J; Xie, T; Zeng, H; Zhou, X | 1 |
| Jianfang, F; Jianrong, L; Jie, M; Jing, X; Jingxuan, L; Kaiyan, M; Mengying, L; Qian, X; Qingzhen, H; Qiuhe, J; Taixiong, C; Wanxia, X; Wenjuan, Y; Xiling, G | 1 |
| Andersen, MS; Bas, F; Bassols, J; Darendeliler, F; de Zegher, F; Díaz, M; Dieris, B; Fanelli, F; Fröhlich-Reiterer, E; Gambineri, A; Garcia-Beltran, C; Glintborg, D; Ibáñez, L; López-Bermejo, A; Malpique, R; Mann, C; Marin, S; Obermayer-Pietsch, B; Ravn, P; Reinehr, T; Renzulli, M; Salvador, C; Singer, V; Torres, JV; Vanky, E; Yildiz, M; Ødegård, R | 1 |
96 review(s) available for metformin and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1996 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2004 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Gliclazide; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Stroke; Thiazolidinediones | 2004 |
Thiazolidinediones for treatment of polycystic ovary syndrome.
Topics: Adult; Chromans; Clinical Trials as Topic; Clomiphene; Contraceptives, Oral; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Troglitazone | 2005 |
Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metabolic Syndrome; Metformin; Middle Aged; Multicenter Studies as Topic; Pioglitazone; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Treatment of nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Body Mass Index; Fatty Liver; Humans; Hypolipidemic Agents; Liver Transplantation; Metformin; Pioglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid; Weight Loss | 2006 |
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Up-Regulation | 2006 |
Thiazolidinedione derivatives in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Metformin and pioglitazone: Effectively treating insulin resistance.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Thiazolidinediones | 2006 |
A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2006 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Metformin; Obesity; Pioglitazone; PPAR gamma; Thiazolidinediones; Treatment Outcome | 2006 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Angiopathies; Disease Progression; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin Resistance; Macrophages; Metformin; Pioglitazone; PPAR gamma; Thiazolidinediones | 2006 |
Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Black People; Body Weight; Drug Combinations; Female; Hispanic or Latino; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Metformin; Middle Aged; Pioglitazone; Sex Factors; Therapeutic Equivalency; Thiazolidinediones; White People | 2007 |
Pioglitazone and metformin.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Therapeutic Equivalency; Thiazolidinediones | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infant, Newborn; Lactation; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Initiating insulin in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Family Practice; Female; Hemoglobin A; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
[Current evidence-based medicine for early intervention in diabetes].
Topics: Diabetes Complications; Diabetes Mellitus; Diet, Diabetic; Evidence-Based Medicine; Exercise Therapy; Humans; Hypoglycemic Agents; Insulin; Life Style; Metformin; Patient Education as Topic; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Pioglitazone; Probucol; Randomized Controlled Trials as Topic; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2009 |
[Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
Topics: Animals; Arteriosclerosis; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Lipid Metabolism; Metformin; Pioglitazone; PPAR gamma; Thiazolidinediones | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
Topics: Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Thiazolidinediones | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Predisposition to Disease; Humans; Hyperlipidemia, Familial Combined; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Models, Biological; Obesity; Pioglitazone; Risk Factors; Thiazolidinediones; Transcription Factors; Triglycerides | 2010 |
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Testosterone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; United States | 2012 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Testosterone; Thiazolidinediones | 2012 |
Drug-induced hypoglycaemia in type 2 diabetes.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2012 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Postprandial Period; Practice Patterns, Physicians'; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2013 |
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2014 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Fractures, Spontaneous; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Urinary Bladder Neoplasms; Weight Gain | 2013 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance, Multiple; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Overweight; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Topics: Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Insulin; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; Female; Flutamide; Humans; Hypoglycemic Agents; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Research Design; Spironolactone; Systematic Reviews as Topic; Thiazolidinediones; Young Adult | 2015 |
Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2016 |
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Repurposing Drugs for Cancer Prevention.
Topics: Anticarcinogenic Agents; Aspirin; Drug Repositioning; Humans; Metformin; Neoplasms; Pioglitazone; Thiazolidinediones | 2016 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models, Animal; Female; Guanine Nucleotide Exchange Factors; Humans; Hyperandrogenism; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Progesterone Reductase; Steroid 17-alpha-Hydroxylase; Theca Cells; Thiazolidinediones | 2016 |
A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
Topics: Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoglycemic Agents; Lithium; Metformin; Pancreatic Neoplasms; Pioglitazone; Prognosis; Signal Transduction; Thiazolidinediones | 2016 |
Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nausea; Peptides; Pioglitazone; Postprandial Period; Sulfonylurea Compounds; Thiazolidinediones; Vomiting | 2017 |
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Triglycerides | 2017 |
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; India; Metformin; Pioglitazone; Thiazolidinediones | 2016 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2017 |
Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Metformin; Pioglitazone; Pregnancy; Risk Factors; Thiazolidinediones | 2017 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.
Topics: Acid-Base Equilibrium; Acid-Base Imbalance; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Water-Electrolyte Imbalance | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones | 2017 |
Antidiabetic drugs and stroke risk. Current evidence.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiazolidinediones | 2018 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin Resistance; Live Birth; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus; Drug Repositioning; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Male; Metformin; Pioglitazone; Thiazolidinediones | 2018 |
Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Protective Factors; Risk Factors; Sulfonylurea Compounds; Treatment Outcome | 2018 |
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2018 |
The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
Topics: Cardiovascular System; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2018 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins | 2019 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2020 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Inflammation; Metformin; Pioglitazone; Risk Factors; SARS-CoV-2; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatment Outcome | 2021 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Placebos; Randomized Controlled Trials as Topic; Risk | 2020 |
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Body Weight; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Glycated Hemoglobin; Glycosylation; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Metformin; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Reproducibility of Results; Risk; Treatment Outcome | 2021 |
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic | 2022 |
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
Investigating the pro-cognitive and anti-depressant efficacy of metformin: A systematic review and meta-analysis of randomised controlled trials.
Topics: Cognition; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic | 2022 |
Diabetes mellitus and multiple myeloma; common features of two distinct entities.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Multiple Myeloma; Pioglitazone | 2022 |
Intestinal lipid absorption and transport in type 2 diabetes.
Topics: Apolipoprotein B-48; Cholesterol; Chylomicron Remnants; Chylomicrons; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hyperlipidemias; Insulin; Intestinal Absorption; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; Metformin; Pioglitazone; Postprandial Period; Sodium; Triglycerides | 2022 |
Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Sulfonylurea Compounds | 2022 |
Are the antidepressant effects of insulin-sensitizing medications related to improvements in metabolic markers?
Topics: Antidepressive Agents; Antipsychotic Agents; Insulin; Metformin; Pioglitazone | 2022 |
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Network Meta-Analysis; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Randomized Controlled Trials as Topic | 2023 |
207 trial(s) available for metformin and pioglitazone
| Article | Year |
|---|---|
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazoles; Thiazolidinediones | 2000 |
The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Humans; Hypoglycemic Agents; Lymphokines; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
[The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
Topics: Blood Pressure; Body Weight; Cholesterol; Consumer Product Safety; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones; Triglycerides | 2004 |
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Triglycerides | 2004 |
[The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].
Topics: Acarbose; Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones | 2003 |
Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Cholesterol; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2004 |
Comparison of pioglitazone and metformin efficacy using homeostasis model assessment.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2004 |
Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2004 |
Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Pioglitazone reduces blood pressure in non-dipping diabetic patients.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2004 |
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Gliclazide; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Thiazolidinediones; Treatment Outcome; Triglycerides | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Thiazolidinediones; Treatment Outcome | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Metformin; Middle Aged; Muscles; Pioglitazone; Thiazolidinediones; Tissue Distribution | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Menstrual Cycle; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Prolactin; Thiazolidinediones | 2005 |
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Reproducibility of Results; Safety; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2005 |
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; gamma-Glutamyltransferase; Gliclazide; Glycated Hemoglobin; Hematocrit; Humans; Hypoglycemic Agents; Leukocyte Count; Male; Metformin; Middle Aged; Pioglitazone; Platelet Count; Thiazolidinediones | 2005 |
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver Diseases; Liver Extracts; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2005 |
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Chemokine CCL2; Cytokines; Gene Expression; Humans; Hypoglycemic Agents; Insulin Resistance; Macrophages; Metformin; Middle Aged; Muscles; Obesity; Pioglitazone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones | 2005 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Gliclazide; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Metformin; Middle Aged; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Triglycerides | 2005 |
Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Particle Size; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2004 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2006 |
Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin.
Topics: Adiponectin; Aged; Carotid Artery, Common; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Thiazolidinediones; Ultrasonography | 2006 |
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Primary Health Care; Prospective Studies; Thiazolidinediones; Treatment Outcome | 2006 |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2006 |
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.
Topics: Adiponectin; Administration, Oral; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pioglitazone; Proinsulin; Prospective Studies; Statistics, Nonparametric; Thiazolidinediones | 2006 |
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes.
Topics: Adult; Aged; Arginine; Body Composition; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Risk Factors; Thiazolidinediones | 2007 |
Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Postprandial Period; Prospective Studies; Regression Analysis; Statistics, Nonparametric; Thiazolidinediones; Treatment Outcome; Triglycerides | 2006 |
Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Black People; Body Weight; Drug Combinations; Female; Hispanic or Latino; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Metformin; Middle Aged; Pioglitazone; Sex Factors; Therapeutic Equivalency; Thiazolidinediones; White People | 2007 |
Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Drug Combinations; Female; Food; Humans; Hypoglycemic Agents; Intestinal Absorption; Least-Squares Analysis; Male; Metformin; Middle Aged; Pioglitazone; Therapeutic Equivalency; Thiazolidinediones; Time Factors | 2007 |
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Topics: Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Male; Metformin; Pioglitazone; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Female; Flutamide; Glucose Tolerance Test; Hormones; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Lipids; Metformin; Pioglitazone; Thiazolidinediones; Ultrasonography | 2007 |
Weight gain in type 2 diabetes mellitus.
Topics: Adipose Tissue; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Female; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Lipids; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Peptide Hormones; Pioglitazone; Prospective Studies; Thiazolidinediones; Weight Gain | 2007 |
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Topics: Adiponectin; Aged; Aldosterone; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Fasting; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; von Willebrand Factor | 2007 |
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Safety; Thiazolidinediones | 2007 |
Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Time Factors | 2007 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glycerol; Glycogenolysis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Liver; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones | 2008 |
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Glyburide; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2008 |
Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Topics: Adult; Aged; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin, Isophane; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2009 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Metformin; Nicotinamide Phosphoribosyltransferase; Pioglitazone; Thiazolidinediones; Young Adult | 2008 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2008 |
2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?
Topics: Area Under Curve; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Ghrelin; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Statistics, Nonparametric; Thiazolidinediones | 2008 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lactones; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Weight Gain | 2008 |
Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-HS-Glycoprotein; Blood Proteins; Diabetes Mellitus, Type 2; Exercise; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pioglitazone; Thiazolidinediones; Waist Circumference | 2008 |
Pioglitazone reduces monocyte activation in type 2 diabetes.
Topics: C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipopolysaccharides; Metformin; Monocytes; Pioglitazone; Thiazolidinediones | 2009 |
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
Topics: Adiponectin; Adult; Aged; Benzamides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Heart Function Tests; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2008 |
Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Topics: Adolescent; Androgen Antagonists; Androgens; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Pilot Projects; Pioglitazone; Progestins; Thiazolidinediones; Young Adult | 2009 |
[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides | 2009 |
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Topics: Adult; Aged; Anthropometry; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Waist Circumference; Weight Gain | 2009 |
Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Gliclazide; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones; Treatment Outcome | 2009 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids; Glycated Hemoglobin; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Middle Aged; Myocardium; Phosphocreatine; Pioglitazone; PPAR alpha; Radionuclide Imaging; Stroke Volume; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Motor Activity; Patient Education as Topic; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Weight Loss; Young Adult | 2009 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2009 |
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2009 |
Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.
Topics: Adipocytes; Adiponectin; Adult; Aged; CD36 Antigens; Cell Line; Coculture Techniques; Down-Regulation; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Macrophages; Male; Metformin; Middle Aged; Obesity; Pioglitazone; Receptors, Scavenger; RNA, Messenger; Scavenger Receptors, Class A; Scavenger Receptors, Class E; Subcutaneous Fat; Thiazolidinediones; Treatment Outcome; Young Adult | 2009 |
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Topics: Adult; Aged; Algorithms; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus.
Topics: Abdominal Fat; Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Organ Size; Pericardium; Pioglitazone; Placebos; Thiazolidinediones | 2010 |
Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Rate; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Patient Selection; Pioglitazone; Radioimmunoassay; Thiazolidinediones; Treatment Outcome; Ultrasonography; Waist Circumference | 2009 |
Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.
Topics: Abdominal Fat; Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2011 |
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Topics: Aged; Atherosclerosis; Biomarkers; Blood Glucose; Body Weight; Bone Density; Collagen; Diabetes Mellitus, Type 2; Female; Femur Neck; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Lumbar Vertebrae; Male; Metformin; Middle Aged; Osteocalcin; Osteoporosis; Pioglitazone; Radius; Risk Assessment; Thiazolidinediones; Ultrasonography | 2010 |
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Topics: Adiponectin; Administration, Oral; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Infusion Systems; Male; Metformin; Middle Aged; Pilot Projects; Pioglitazone; Proinsulin; Prospective Studies; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
Topics: Apolipoprotein B-100; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2010 |
Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes.
Topics: Age of Onset; Body Fat Distribution; Chromatography, Gel; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Metformin; Middle Aged; Particle Size; Pioglitazone; Thiazolidinediones; Time Factors | 2010 |
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Topics: Analysis of Variance; Blood Pressure; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Natriuretic Peptide, Brain; Pioglitazone; Sodium, Dietary; Thiazolidinediones | 2010 |
Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Topics: Adolescent; Alanine Transaminase; Androgens; Androstenes; Aspartate Aminotransferases; Blood Glucose; Body Composition; C-Reactive Protein; Cholesterol; Cross-Over Studies; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; gamma-Glutamyltransferase; Humans; Hydro-Lyases; Insulin; Longitudinal Studies; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Tunica Intima; Young Adult | 2010 |
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erythrocyte Deformability; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Stress, Mechanical; Sulfonylurea Compounds; Thiazolidinediones | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adolescent; Adult; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Risk Factors; Thiazolidinediones; Vasodilation; Young Adult | 2011 |
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Topics: Acarbose; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Interleukin-6; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2010 |
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Thiazolidinediones | 2011 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Risk Factors; Thiazolidinediones | 2010 |
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Sensitivity and Specificity; Thiazolidinediones; Venoms | 2011 |
Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).
Topics: Adult; Aged; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metabolome; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2011 |
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Cell Survival; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelial Cells; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Pioglitazone; Stem Cells; Thiazolidinediones | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Male; Metformin; Mexican Americans; Middle Aged; Muscle, Skeletal; Myositis; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tunica Intima | 2011 |
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Young Adult | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2011 |
Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
Topics: Aged; Arginine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lysine; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Time Factors | 2011 |
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Pioglitazone; Postprandial Period; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2011 |
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Ligands; Male; Metformin; Middle Aged; Pioglitazone; Platelet Function Tests; Sulfonylurea Compounds; Thiazolidinediones; Thromboxanes; von Willebrand Factor | 2011 |
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Fasting; Fatty Acids, Nonesterified; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Spectroscopy; Metformin; Middle Aged; Obesity; Peptides; Pioglitazone; PPAR gamma; Receptors, Glucagon; Thiazolidinediones; Triglycerides; Venoms | 2011 |
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2011 |
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
Topics: Adiponectin; Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Pioglitazone; Risk Factors; Thiazolidinediones | 2011 |
Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Renin-Angiotensin System; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combinations; Estrogens; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Edema; Exenatide; Fatty Liver; Female; Fibroblast Growth Factors; Humans; Hypoglycemic Agents; Liver; Lower Extremity; Male; Metformin; Mice; Middle Aged; Nausea; Non-alcoholic Fatty Liver Disease; Obesity; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2011 |
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.
Topics: Aged; Biomarkers; Brachial Artery; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Greece; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vasodilation | 2012 |
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2012 |
Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes.
Topics: Adult; Age of Onset; Diabetes Mellitus, Type 1; Disease Progression; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2011 |
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Linear Models; Male; Metformin; Middle Aged; Outpatients; Pioglitazone; Regression Analysis; Thiazolidinediones | 2010 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liquid; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Health; Humans; Linoleic Acid; Lipoproteins; Magnetic Resonance Spectroscopy; Metabolomics; Metformin; Multivariate Analysis; Oxidation-Reduction; Pioglitazone; Polycystic Ovary Syndrome; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Young Adult | 2011 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Biomarkers; Bone and Bones; Bone Morphogenetic Proteins; Bone Remodeling; Diabetes Mellitus, Type 2; Double-Blind Method; Genetic Markers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2012 |
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2012 |
Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Middle Aged; Pioglitazone; Polycystic Ovary Syndrome; Risk; Thiazolidinediones; Treatment Outcome; Triglycerides | 2012 |
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Placebos; Thiazolidinediones; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2012 |
Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Drug Therapy, Combination; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Metformin; Pioglitazone; Thiazolidinediones | 2012 |
β-cell function preservation after 3.5 years of intensive diabetes therapy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Patient Compliance; Pioglitazone; Thiazolidinediones | 2012 |
Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Angiopoietin-Like Protein 4; Angiopoietins; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Body Composition; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug Combinations; Ethinyl Estradiol; Female; Flutamide; Gene Expression; Humans; Hyperandrogenism; Hypoglycemic Agents; Leptin; Metformin; Pioglitazone; Receptors, Cell Surface; Receptors, Tumor Necrosis Factor; Subcutaneous Fat; Thiazolidinediones; TWEAK Receptor | 2012 |
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Triglycerides; Young Adult | 2012 |
Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Testosterone; Thiazolidinediones | 2013 |
Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dizziness; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nausea; Peptides; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2013 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones | 2013 |
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms | 2012 |
Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.
Topics: Apelin; Blood Glucose; Body Mass Index; Chemokines; Diabetes Mellitus, Type 2; Dinoprost; Humans; Hypoglycemic Agents; Inflammation; Intercellular Signaling Peptides and Proteins; Metformin; Pioglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2012 |
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Quality of Life; Risk Factors; Sulfonylurea Compounds; Surveys and Questionnaires; Thiazolidinediones; Treatment Outcome | 2012 |
Treatment with pioglitazone is associated with decreased preprandial ghrelin levels: a randomized clinical trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Ghrelin; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2013 |
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial.
Topics: Adult; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Female; GPI-Linked Proteins; Humans; Hypoglycemic Agents; Lectins; Leptin; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2013 |
Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Oxidative Stress; Pioglitazone; Platelet Activation; Thiazolidinediones; Treatment Outcome | 2013 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Homeostasis; Humans; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Models, Biological; Pioglitazone; Placebos; Thiazolidinediones | 2013 |
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Fluorobenzenes; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Intra-Abdominal Fat; Italy; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography | 2013 |
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Male; Metformin; Middle Aged; Patient Dropouts; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Weight Loss | 2013 |
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss | 2014 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Metformin; Muscle, Skeletal; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones | 2013 |
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Retrospective Studies; Thiazolidinediones; Treatment Outcome | 2013 |
Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
Topics: Activins; Adipose Tissue; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Double-Blind Method; Fluorodeoxyglucose F18; Glucose; Heart; Heart Ventricles; Humans; Hypoglycemic Agents; Inhibin-beta Subunits; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Myocardium; Myocytes, Cardiac; Organ Size; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Thiazolidinediones; Treatment Outcome; Ventricular Remodeling | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2014 |
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Risk Factors; Thiazolidinediones | 2014 |
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; PPAR gamma; Prospective Studies; Quinolines; Sulfonamides; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Weight Gain | 2014 |
Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptides; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Recombinant Fusion Proteins; Thiazolidinediones; Venoms | 2014 |
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Treatment Outcome | 2014 |
Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Middle Aged; Pilot Projects; Pioglitazone; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Thiazolidinediones; Viral Load | 2014 |
Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases.
Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Male; Metformin; Middle Aged; Pioglitazone; Retinol-Binding Proteins, Plasma; Thiazolidinediones | 2014 |
Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.
Topics: Adipokines; Biomarkers; Chitinase-3-Like Protein 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lectins; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Pharmacokinetic interactions between topiramate and pioglitazone and metformin.
Topics: Adolescent; Adult; Analysis of Variance; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Female; Fructose; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Tandem Mass Spectrometry; Thiazolidinediones; Time Factors; Topiramate; Young Adult | 2014 |
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Thiazolidinediones; Venoms; Weight Gain; Weight Loss | 2015 |
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Thiazolidinediones | 2015 |
The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Sex Characteristics; Thiazolidinediones | 2015 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Obesity; Overweight; Pioglitazone; Thiazolidinediones | 2015 |
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Weight Loss | 2015 |
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Factors; Flutamide; Hirsutism; Humans; Hyperandrogenism; Hyperinsulinism; Longitudinal Studies; Metformin; Pioglitazone; Thiazolidinediones | 2016 |
A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Egypt; Female; Fertility Agents, Female; Humans; Infertility, Female; Intention to Treat Analysis; Letrozole; Metformin; Nitriles; Ovulation; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Thiazolidinediones; Triazoles | 2016 |
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Topics: Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Safety; Thiazolidinediones; Uracil | 2015 |
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Topics: Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Hong Kong; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Taiwan; Thiazolidinediones; Treatment Outcome; Uracil | 2017 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Topics: Asia; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2016 |
Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Psoriasis; Severity of Illness Index; Thiazolidinediones | 2016 |
Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Topics: Acarbose; Aged; Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metformin; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2016 |
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate; Spleen; Thiazolidinediones; Tomography, X-Ray Computed | 2017 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Meals; Metformin; Obesity; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prediabetic State; Prevalence; Slovenia; Thiazolidinediones; Uracil | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss | 2017 |
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Intra-Abdominal Fat; Levonorgestrel; Metformin; Oligomenorrhea; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones | 2017 |
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2017 |
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prediabetic State; Retrospective Studies; Risk Factors; Risk Reduction Behavior; Treatment Outcome | 2018 |
Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prognosis; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; S100 Calcium-Binding Protein A4; Spironolactone | 2019 |
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Iran; Lipids; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Reduction Behavior; Silymarin; Time Factors; Treatment Outcome; Vitamin E; Waist Circumference; Young Adult | 2019 |
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study.
Topics: Adult; Aged; Antimalarials; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Treatment Failure | 2020 |
Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Topics: Adult; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Interleukin-6; Interleukin-8; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Prognosis; Young Adult | 2019 |
Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
Topics: Adolescent; Biomarkers; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Pilot Projects; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome | 2020 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Testosterone; Vitamin D; Young Adult | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemokines, CXC; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Ethinyl Estradiol; Female; Gene Expression; Genetic Diseases, X-Linked; Gigantism; Heart Defects, Congenital; Humans; Hypoglycemic Agents; Insulin Resistance; Intellectual Disability; Levonorgestrel; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome | 2020 |
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study.
Topics: Adult; Anxiety; Comorbidity; Depression; Female; Humans; Inflammasomes; Metformin; NLR Family, Pyrin Domain-Containing 3 Protein; Outpatients; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Psychological Distress; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2020 |
Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; New Zealand; Pioglitazone; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin | 2020 |
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Male; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Young Adult | 2021 |
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds | 2021 |
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil | 2022 |
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2022 |
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hormone; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Resveratrol; Stress, Psychological; Testosterone; Young Adult | 2023 |
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Preference; Pioglitazone; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Humans; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2023 |
Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
Topics: Adolescent; Cyproterone Acetate; Diabetes Mellitus, Type 2; Female; Follistatin; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Polycystic Ovary Syndrome | 2023 |
Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Tablets | 2023 |
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a mult
Topics: Adolescent; Carotid Intima-Media Thickness; Clinical Trials, Phase II as Topic; Female; Humans; Insulin; Life Style; Metformin; Multicenter Studies as Topic; Pioglitazone; Polycystic Ovary Syndrome; Quality of Life; Randomized Controlled Trials as Topic; Spironolactone; Young Adult | 2023 |
189 other study(ies) available for metformin and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Humans; Indoleacetic Acids; Mice; Mice, Mutant Strains; Molecular Structure | 2015 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Molecular Structure; Murraya; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin | 2016 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
Discovery of tetrahydrocarbazoles with potent hypoglycemic and hypolipemic activities.
Topics: Blood Glucose; Body Weight; Carbazoles; Dose-Response Relationship, Drug; Drug Discovery; Hep G2 Cells; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Molecular Structure; Structure-Activity Relationship | 2018 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.
Topics: Animals; Antihypertensive Agents; Insulin; Male; Metformin; Pioglitazone; Rats; Rats, Sprague-Dawley; Sodium; Thiazoles; Thiazolidinediones | 1994 |
Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation.
Topics: Animals; Aorta, Thoracic; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1996 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Neoplasms, Experimental; Metformin; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Disparate effects of antidiabetic drugs on arterial contraction.
Topics: Animals; Arteries; Blood Pressure; Glyburide; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Male; Metformin; Muscle Contraction; Muscle, Smooth, Vascular; Pioglitazone; Potassium Chloride; Rats; Rats, Wistar; Tail; Thiazoles; Thiazolidinediones | 1997 |
Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation.
Topics: Enzyme-Linked Immunosorbent Assay; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Metformin; Pentoxifylline; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.
Topics: 3-Hydroxysteroid Dehydrogenases; Biguanides; Chromans; Cloning, Molecular; Humans; Kinetics; Metformin; Pioglitazone; Recombinant Proteins; Saccharomyces cerevisiae; Steroid 17-alpha-Hydroxylase; Steroid Hydroxylases; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Eating; Glycogen; Hypoglycemic Agents; Ketone Bodies; Liver; Male; Metformin; Muscle, Skeletal; Obesity; Organ Size; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Wistar; Rats, Zucker; Streptozocin; Thiazoles; Thiazolidinediones | 2002 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hypoglycemic Agents; Isometric Contraction; Lipid Peroxidation; Lipids; Male; Metformin; Muscle Contraction; Muscle Relaxation; Oxidation-Reduction; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.
Topics: Adipocytes; Adipose Tissue; Adult; Cells, Cultured; Chromans; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Kinetics; Metformin; Pioglitazone; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Topics: Adolescent; Adult; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Menstrual Cycle; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Safety; Thiazolidinediones; Treatment Outcome; Weight Loss | 2003 |
Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Hypoglycemic Agents; Metformin; Pharmaceutical Preparations; Pioglitazone; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazolidinediones | 2004 |
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
Topics: Animals; Electron Transport Complex I; Energy Metabolism; Hypoglycemic Agents; Male; Metformin; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Potassium Chloride; Rats; Rats, Sprague-Dawley; Rosiglitazone; Rotenone; Thiazolidinediones | 2004 |
[Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2004 |
Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2003 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Hemoglobins; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metformin; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Precursors; Rats; Rats, Zucker; Thiazolidinediones | 2004 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Pioglitazone; Thiazolidinediones; Time Factors | 2004 |
Regarding the use of HOMA to aid drug selection.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2005 |
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Liver Failure; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pioglitazone; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2005 |
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Metformin; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.
Topics: Abdominal Fat; Adiponectin; Adult; Blood Glucose; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Leptin; Metformin; Middle Aged; Pioglitazone; Resistin; Thiazolidinediones | 2006 |
Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin.
Topics: Blood Glucose; Central Nervous System Cysts; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Insulin; Insulin Resistance; Magnetic Resonance Imaging; Metformin; Middle Aged; Pioglitazone; Pituitary-Adrenal System; Thiazolidinediones | 2005 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
New drugs.
Topics: Anti-Inflammatory Agents; Anticonvulsants; Drug Combinations; gamma-Aminobutyric Acid; Humans; Hypoglycemic Agents; Immunoglobulins, Intravenous; Immunologic Factors; Metformin; Mometasone Furoate; Pioglitazone; Pregabalin; Pregnadienediols; Thiazolidinediones | 2005 |
Pioglitazone/metformin (Actoplus met).
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2006 |
Tissue-specific regulation of malonyl-CoA decarboxylase activity in OLETF rats.
Topics: Animals; Body Weight; Carboxy-Lyases; Cholesterol; Fasting; Fatty Acids, Nonesterified; Glucose; Hypoglycemic Agents; Insulin; Male; Metformin; Muscle, Skeletal; Myocardium; Pioglitazone; Rats; Rats, Inbred OLETF; RNA, Messenger; Thiazolidinediones; Triglycerides | 2006 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hypoglycemic Agents; Immunohistochemistry; Insulin; Metformin; Ovary; Pioglitazone; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Testosterone; Thiazolidinediones; Troglitazone | 2006 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Models, Biological; Multicenter Studies as Topic; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2006 |
Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exophthalmos; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Logistic Models; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Pioglitazone/metformin.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
[The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Risk Factors; Thiazolidinediones | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Lipid Metabolism; Metformin; Muscle, Skeletal; Nicotinamide Phosphoribosyltransferase; Obesity; Pioglitazone; RNA, Messenger; Thiazolidinediones | 2007 |
Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes.
Topics: Animals; Cyclophosphamide; Cytokines; Diabetes Mellitus, Type 1; Disease Progression; Female; Immunosuppressive Agents; Incidence; Islets of Langerhans; Metformin; Mice; Mice, Inbred NOD; Pioglitazone; Random Allocation; Spleen; Thiazolidinediones | 2006 |
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Topics: Blood Glucose; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Models, Economic; Monte Carlo Method; Pioglitazone; Rosiglitazone; Thiazolidinediones; United Kingdom | 2007 |
Hospital admission associated with Medicare Part D "doughnut hole".
Topics: Aged; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Medicare; Metformin; Patient Readmission; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglitazone; Prediabetic State; Rats; Rats, Inbred OLETF; Thiazolidinediones; Weight Gain; Weight Loss | 2007 |
[Status of glitazones in treatment of type 2 diabetes mellitus].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Management; Drug Costs; Drug Therapy, Combination; Germany; Glyburide; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Pioglitazone; Practice Guidelines as Topic; Survival Analysis; Thiazolidinediones | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mass Index; Cell Fractionation; Chemokine CCL2; Gene Expression; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Metformin; Middle Aged; Muscle, Skeletal; Obesity; Pioglitazone; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; RNA, Messenger; Thiazolidinediones | 2007 |
Pioglitazone: an anti-diabetic compound with anti-aging properties.
Topics: Animals; Basal Metabolism; Dose-Response Relationship, Drug; Drosophila melanogaster; Fertility; Glipizide; Hypoglycemic Agents; Insulin; Longevity; Metformin; Models, Biological; Pioglitazone; Population Density; Research Design; Rosiglitazone; Sexual Behavior, Animal; Signal Transduction; Thiazolidinediones; Time Factors | 2007 |
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Humans; Hypoglycemic Agents; Lipids; Liver Function Tests; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pioglitazone; Thiazolidinediones | 2008 |
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2007 |
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Topics: Abdominal Fat; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Liver; Male; Metformin; Middle Aged; Muscle, Skeletal; Pioglitazone; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Thiazolidinediones | 2007 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metformin; Middle Aged; Pioglitazone; Polycystic Ovary Syndrome; Risk Assessment; Thiazolidinediones; Treatment Outcome | 2008 |
The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glucagon-Like Peptide 1; Humans; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones | 2008 |
Clinical decisions. Management of type 2 diabetes--polling results.
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Infertility, Female; Insemination, Artificial, Homologous; Laparoscopy; Life Style; Metformin; Obesity; Ovary; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Pregnancy; Randomized Controlled Trials as Topic; Thiazolidinediones | 2008 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Outcome Assessment, Health Care; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Pioglitazone; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonylurea Compounds; Tablets; Thiazolidinediones | 2008 |
Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness.
Topics: Adipocytes; Adult; Aged; Animals; Female; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mice, Obese; Middle Aged; Muscle, Skeletal; Obesity; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Stearoyl-CoA Desaturase; Thiazolidinediones; Transfection; Young Adult | 2008 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycerol; Heparin; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Area Under Curve; Chromatography, Liquid; Drug Interactions; Female; Fenofibrate; Fumarates; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Renin; Tandem Mass Spectrometry; Thiazolidinediones | 2008 |
Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
Topics: Acanthosis Nigricans; Adolescent; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy, Familial Partial; Metformin; Pioglitazone; Thiazolidinediones | 2008 |
Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
Topics: Adipose Tissue; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lamin Type A; Lipodystrophy, Familial Partial; Metformin; Middle Aged; Pioglitazone; Portugal; Thiazolidinediones; Treatment Outcome | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids; Female; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Myocardium; Oxidation-Reduction; Pioglitazone; PPAR alpha; Sulfonylurea Compounds; Thiazolidinediones; Ventricular Dysfunction, Left | 2009 |
Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations.
Topics: Adenosine Triphosphate; Animals; Berberine; Cell Line; Fatty Acids; Glucose; Hypoglycemic Agents; Immunoblotting; In Vitro Techniques; Insulin; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Lipid Metabolism; Membrane Potential, Mitochondrial; Metformin; Pioglitazone; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Thiazolidinediones | 2009 |
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2009 |
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
Topics: Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones and clinical outcomes in type 2 diabetes.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Medical Records Systems, Computerized; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Regression Analysis; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2009 |
Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
Topics: Acylation; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Ghrelin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Postprandial Period; Satiety Response; Thiazolidinediones; Time Factors | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Clinical evaluation of combined therapy for type 2 diabetes.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2010 |
Simultaneous determination of metformin hydrochloride and pioglitazone hydrochloride in binary mixture and in their ternary mixture with pioglitazone acid degradate using spectrophotometric and chemometric methods.
Topics: Analysis of Variance; Drug Combinations; Hypoglycemic Agents; Least-Squares Analysis; Metformin; Pioglitazone; Principal Component Analysis; Regression Analysis; Spectrophotometry; Technology, Pharmaceutical; Thiazolidinediones | 2009 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Thiazolidinediones; Weight Gain | 2010 |
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Dietary Fats; Glucose Intolerance; Glucose-6-Phosphatase; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rats; Rats, Wistar; Streptozocin; Thiazolidinediones | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Generation, validation and humanisation of a novel insulin resistant cell model.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Obesity; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Thiazolidinediones | 2010 |
A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Costs; Female; Health Care Costs; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Young Adult | 2010 |
Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Adipose Tissue; Bicycling; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipase; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Receptors, Adiponectin; Thiazolidinediones | 2011 |
Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2011 |
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Pioglitazone; Registries; Retrospective Studies; Thiazolidinediones | 2011 |
Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Edema; Family; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Military Personnel; Pioglitazone; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2009 |
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Greece; Humans; Hypoglycemic Agents; Lipids; Logistic Models; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Risk Assessment; Risk Factors; Spain; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Venoms | 2011 |
Determinants of an optimal response to pioglitazone in terms of HDL-cholesterol.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2011 |
[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2011 |
Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Medication Adherence; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Thiazolidinediones; Young Adult | 2011 |
Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Thiazolidinediones | 2012 |
Role of activation of 5'-adenosine monophosphate-activated protein kinase in gastric ulcer healing in diabetic rats.
Topics: Acetic Acid; Animals; Blood Glucose; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Metformin; Neovascularization, Physiologic; Pioglitazone; Pyrimidines; Rats; Rats, Wistar; Stomach; Stomach Ulcer; Thiazolidinediones; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2011 |
Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells.
Topics: Apoptosis; Benzimidazoles; Biphenyl Compounds; Cardiotonic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Fluorobenzenes; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones | 2012 |
High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.
Topics: Chromatography, High Pressure Liquid; Drinking Water; Glyburide; Hydrogen-Ion Concentration; Hypoglycemic Agents; Mass Spectrometry; Metformin; Pioglitazone; Reproducibility of Results; Rivers; Sensitivity and Specificity; Sodium Dodecyl Sulfate; Solid Phase Extraction; Thiazolidinediones; Water Pollutants, Chemical | 2012 |
Non-alcoholic fatty liver disease in children.
Topics: Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver; Metformin; Obesity; Pioglitazone; Thiazolidinediones; Transaminases; Weight Loss | 2012 |
[Fixed dose of combination of pioglitazone/metformin].
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Metformin; Pioglitazone; Thiazolidinediones | 2012 |
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subunit; Fatty Acid-Binding Proteins; Female; Femur; Insulin Resistance; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2012 |
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.
Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Injections, Intraventricular; Injections, Spinal; Metformin; Mice; Mice, Inbred ICR; Pioglitazone; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Blood Glucose; Breast Neoplasms; Case-Control Studies; Deoxyguanosine; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Metformin; Pioglitazone; Prognosis; Thiazolidinediones | 2012 |
Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS.
Topics: Animals; Chromatography, Liquid; Dogs; Drug Stability; Female; Limit of Detection; Linear Models; Male; Metformin; Pioglitazone; Reproducibility of Results; Tandem Mass Spectrometry; Thiazolidinediones | 2014 |
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Middle Aged; Nutrition Surveys; Pioglitazone; Rosiglitazone; Thiazolidinediones; United States | 2013 |
Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Male; Metformin; Pioglitazone; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazolidinediones | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Inbred OLETF; Telmisartan; Thiazolidinediones | 2013 |
Impact of a combined high cholesterol diet and high glucose environment on vasculature.
Topics: Animals; Cholesterol; Diabetes Mellitus; Glucose; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones; Zebrafish | 2013 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Detecting protein carbonylation in adipose tissue and in cultured adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Aldehydes; Animals; Antibodies; Biotin; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; Protein Carbonylation; Proteins; Thiazolidinediones | 2014 |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2014 |
Beneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.
Topics: Adipokines; Animals; Chemokines; Disease Models, Animal; Drug Combinations; Drug Resistance; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Humans; Hyperandrogenism; Hyperinsulinism; Menstruation Disturbances; Metformin; Obesity; Pioglitazone; Thiazolidinediones | 2014 |
A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones; United States | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Fasting; Female; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resistance; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Testosterone; Thiazolidinediones; Triglycerides; Young Adult | 2014 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult | 2014 |
Disseminated cryptococcosis in a diabetic patient.
Topics: Administration, Oral; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fluconazole; Glipizide; Humans; Hypoglycemic Agents; Immunocompromised Host; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation.
Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diffusion; Dogs; Drug Combinations; Drug Delivery Systems; Drug Liberation; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Tablets; Thiazolidinediones; Time Factors | 2014 |
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.
Topics: Body Mass Index; Clinical Protocols; Comorbidity; Decision Support Systems, Clinical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Drug Therapy, Combination; Europe; Expert Testimony; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Life Expectancy; Metformin; Pioglitazone; Precision Medicine; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Comparative effects of metformin and pioglitazone on lipid profile of rabbits.
Topics: Animals; Female; Hypoglycemic Agents; Lipids; Male; Metformin; Pioglitazone; Rabbits; Thiazolidinediones | 2015 |
The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist.
Topics: AMP-Activated Protein Kinases; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Viral; Gene Expression Regulation; Genes, Reporter; Hepacivirus; Hepatocytes; Host-Pathogen Interactions; Humans; Interferon-alpha; Luciferases; Metformin; Pioglitazone; PPAR alpha; PPAR gamma; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Signal Transduction; STAT1 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones | 2015 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Glial Fibrillary Acidic Protein; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Microscopy, Fluorescence; Neuroglia; Neurons; Pain; Pain Management; Pain Measurement; Pioglitazone; PPAR gamma; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2015 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2015 |
Effect of pioglitazone medication on the incidence of dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; Germany; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Protective Factors; Rosiglitazone; Thiazolidinediones | 2015 |
Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2015 |
Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy".
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Goals; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome | 2015 |
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Antihypertensive Agents; Arteries; Cyclic GMP; Dose-Response Relationship, Drug; Drug Interactions; Glucose; Glycolysis; Hypoglycemic Agents; In Vitro Techniques; Metformin; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase 5 Inhibitors; Pioglitazone; Rats; Rosiglitazone; Sildenafil Citrate; Tail; Thiazolidinediones; Vasodilator Agents | 2015 |
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.
Topics: Animals; Bombyx; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Drug Evaluation, Preclinical; Fat Body; Glucose Intolerance; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Metformin; Phenotype; Phosphorylation; Pioglitazone; Thiazolidinediones | 2015 |
Oral combination therapy in primary care.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column.
Topics: Animals; Chromatography, Liquid; Female; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Metformin; Pioglitazone; Rabbits; Reproducibility of Results; Silicon Dioxide; Thiazolidinediones | 2015 |
Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones | 2015 |
Co-Administration of Pioglitazone Improves Fluoxetine's Antinociceptive, Neuroprotective, and Antidepressant Effects in Chronic Constriction Injury in Rats.
Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Chronic Pain; Constriction, Pathologic; Cytokines; Fluoxetine; Hyperalgesia; Hypoglycemic Agents; Male; Metformin; Neuroprotective Agents; Pioglitazone; Postural Balance; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Spinal Cord; Swimming; Thiazolidinediones | 2015 |
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Topics: Adipokines; Anti-Inflammatory Agents; Brain; Cohort Studies; Cytokines; Disability Evaluation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Image Processing, Computer-Assisted; Leptin; Magnetic Resonance Imaging; Male; Metformin; Multiple Sclerosis; Obesity; Pioglitazone; PPAR gamma; RNA, Messenger; Statistics, Nonparametric; T-Lymphocytes, Regulatory; Thiazolidinediones; Time Factors | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus.
Topics: Aged; Asia, Eastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Pioglitazone; Postprandial Period; Randomized Controlled Trials as Topic; Thiazolidinediones; White People | 2017 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine).
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Glipizide; Guanidines; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2016 |
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Pioglitazone; Polyethylene Glycols; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2016 |
Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Cholecalciferol; Coal Tar; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Immunologic Factors; Male; Metformin; Middle Aged; Pioglitazone; Psoriasis; Thiazolidinediones | 2017 |
Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Pioglitazone; Thiazolidinediones | 2017 |
Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.
Topics: Adult; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Interleukin-6; Lipid Metabolism; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones | 2017 |
Identification of tissue-specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics.
Topics: 2,4-Dinitrophenol; Adipose Tissue, White; Aging; Animals; Bezafibrate; Caloric Restriction; Carnitine; Citrate (si)-Synthase; Gene Expression Profiling; Gene Expression Regulation; Glycated Hemoglobin; Interferon-gamma; Male; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Mice, Inbred Strains; Muscle, Skeletal; Myocardium; Neocortex; Pioglitazone; Quercetin; Resveratrol; Sirtuin 3; Stilbenes; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2017 |
Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Interrupted Time Series Analysis; Legislation, Drug; Metformin; Patient Safety; Pharmacoepidemiology; Pioglitazone; Republic of Korea; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones | 2018 |
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferons; Male; Metformin; Middle Aged; Pioglitazone; Sustained Virologic Response | 2017 |
Pioglitazone/metformin adduct regulates insulin secretion and inhibits high glucose-induced apoptosis via p21-p53-MDM2 signaling in INS-1 cells.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Metformin; Pioglitazone; Proto-Oncogene Proteins c-mdm2; Rats; Tumor Suppressor Protein p53 | 2018 |
Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Case-Control Studies; Cell Movement; Cyclophilin A; Cytokines; Diabetes Mellitus, Type 2; Foam Cells; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipoproteins, LDL; Macrophages; Metformin; Middle Aged; Oxidative Stress; Pioglitazone; Reactive Oxygen Species; Signal Transduction; THP-1 Cells | 2018 |
A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Drug Combinations; Equipment Design; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Reference Standards; Reproducibility of Results; Solutions; Tablets; Thiazolidinediones; Uracil | 2016 |
Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
Topics: Animals; Cholesterol; Diet; Disease Models, Animal; Eating; Female; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Organ Size; Pioglitazone; Rats; RNA, Messenger; Thiazolidinediones | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Intolerance; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2018 |
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
Topics: Abscess; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incidence; Liver Abscess; Male; Metformin; Middle Aged; National Health Programs; Pioglitazone; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones; Treatment Outcome | 2018 |
Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association.
Topics: Anticholesteremic Agents; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Magnetic Resonance Imaging; Male; Metformin; Pioglitazone; Tomography, X-Ray Computed | 2018 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Letrozole; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Receptors, LHRH; RNA, Messenger | 2018 |
Trends, in Diagnosis and Treatment of Polycystic Ovarian Syndrome by Specialty.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Diagnostic Tests, Routine; Diuretics; Endocrinologists; Female; General Practitioners; Gynecology; Humans; Hydrocortisone; Hypoglycemic Agents; Life Style; Lipids; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Practice Patterns, Physicians'; Retrospective Studies; Spironolactone; Young Adult | 2016 |
Applications of Fourier transform infrared spectroscopic method for simultaneous quantitation of some hypoglycemic drugs in their binary mixtures.
Topics: Hypoglycemic Agents; Limit of Detection; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sulfonylurea Compounds; Vildagliptin | 2019 |
High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Epithelial Cells; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Signal Transduction; Urinary Bladder | 2019 |
Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones | 2019 |
Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
Topics: Algorithms; Analysis of Variance; Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Tablets | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation; Male; Metformin; Pioglitazone; Prediabetic State; Protein Kinase Inhibitors; Rats, Wistar; rho-Associated Kinases; Signal Transduction; Vasoconstriction | 2019 |
Polycystic ovary syndrome in adolescent girls.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2020 |
Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Electroretinography; Glyburide; Humans; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Male; Metformin; Molecular Structure; Oximes; Pioglitazone; Piperidines; Protective Agents; Rats; Rats, Wistar; Retina | 2020 |
Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Drug Therapy, Combination; Gene Expression; Humans; Metformin; Pioglitazone; Signal Transduction; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2020 |
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Denmark; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Registries | 2020 |
Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
Topics: Adolescent; Female; Gastrointestinal Microbiome; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2021 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.
Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; Humans; Letrozole; Metformin; Phosphatidylinositol 3-Kinases; Pioglitazone; Polycystic Ovary Syndrome; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-akt; Signal Transduction; Spironolactone | 2021 |
Beneficial effects of a plant-fish oil, slow carbohydrate diet on cardio-metabolic health exceed the correcting effects of metformin-pioglitazone in diabetic pigs fed a fast-food diet.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Fast Foods; Fish Oils; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Plant Oils; Swine | 2021 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolome; Metabolomics; Metformin; Mice, Inbred C57BL; Mice, Knockout; Neomycin; Nitric Oxide; Nitric Oxide Synthase Type II; Nitrites; Pioglitazone | 2021 |
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence | 2022 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Rats; Rats, Wistar | 2022 |
DoE-Based Analytical Failure Modes Critical Effect Analysis (AFMCEA) to a Multipurpose-RP-HPLC Method for the Estimation of Multiple FDC Products of Metformin Hydrochloride Using an Analytical Quality by Design Approach.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Humans; Metformin; Pioglitazone; Reproducibility of Results | 2022 |
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taiwan | 2022 |
Metformin, pioglitazone and gout risk.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gout; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2022 |
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
Topics: Acarbose; Animals; Hypoglycemic Agents; Immune Checkpoint Inhibitors; Insulin; Melanoma; Metformin; Mice; Pioglitazone; Sitagliptin Phosphate | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Cholic Acid; Diet, High-Fat; Fibrosis; Glucosides; Inflammation; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats | 2022 |
Does Pten have an impact on oogenesis of PCOS mouse models?
Topics: Animals; Clomiphene; Female; Metformin; Mice; Oogenesis; Ovulation Induction; Phosphatidylinositol 3-Kinases; Pioglitazone; Polycystic Ovary Syndrome; PTEN Phosphohydrolase | 2023 |
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Spironolactone; Thyrotropin | 2023 |
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
Topics: Animals; Female; Hepatocyte Nuclear Factors; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Rats; Sex Hormone-Binding Globulin | 2023 |
Development of Capillary Zone Electrophoresis Method for the Simultaneous Separation and Quantification of Metformin and Pioglitazone in Dosage Forms; and Comparison with HPLC Method.
Topics: Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Indicators and Reagents; Metformin; Pioglitazone; Reproducibility of Results; Tablets | 2023 |
Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.
Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2023 |
Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Thiazolidinediones | 2023 |
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Phosphatidate Phosphatase; Pioglitazone; Polycystic Ovary Syndrome | 2023 |